Know2eat

Echinacea

Echinacea purpurea

Herbs & Botanicals

What echinacea may help with

Ranked by how strong the human evidence is — best supported first.

Best supportedImmune functionLimited evidence· 1 source

Then, in order

About Echinacea

Preparations from the root or aerial parts of three different coneflower species, sold as pressed juice, tincture or dried extract. Alkylamides, caffeic acid derivatives and polysaccharides are the compounds usually measured.

Echinacea is the clearest example in this catalogue of why "the herb" is the wrong unit of analysis. Trials have used three species, two plant parts, and extraction methods from pressed fresh juice to dried root powder — preparations with almost nothing chemically in common. Pooled analyses accordingly disagree with one another, and the largest, best-blinded individual trials have generally been null.

Sold as
Pressed juice, Ethanolic tincture, Dried root capsule, Tablet, Tea
Standardised to
Variously to alkylamides, cichoric acid or echinacoside depending on species — a product without this marker may not resemble what was studied.
Also known as
Purple coneflower, Echinacea angustifolia, Echinacea pallida

Regulation: Registered as a traditional herbal medicine for short-term cold symptoms in several European countries under a framework based on long-standing use rather than proof of effect. UK guidance advises against use in children under 12 following a review of allergic reactions.

What the research used

The amounts, forms and durations published trials of Echinacea actually administered.

These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.

  • Studied for Common cold, starting at symptom onset

    2400–4000 mg

    Limited

    Standardised ethanolic extract of aerial parts and root, divided doses · 5–10 days, or up to 4 months for prophylaxis

    This range is from trials of one branded Swiss preparation. Doses for pressed juice and for dried root products are different numbers entirely and cannot be substituted.

  • Studied for Pressed juice preparations

    900 mg

    Limited

    Pressed juice of Echinacea purpurea aerial parts · 8–10 days

    A separate product family with its own trial history. Comparing its dose with dried-extract doses is not meaningful.

This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.

When it was taken

Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.

None of the timings below were directly compared in a trial. They reflect how the research happened to dose, or what the pharmacology implies — which is not the same as a timing being better.

  • Any time

    Not enough

    Trials instruct starting at the first sign of symptoms and dosing several times daily. That is a treatment schedule from the protocols, not a tested comparison of times of day.

    Timing was not directly compared. This reflects convention or how the compound behaves in the body, not a trial showing this window works better.

The evidence in depth

Best supported: Limited

What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.

Immune function

Immune Health
Limited evidence

Pooled analyses suggest echinacea may shorten a cold by around half a day to a day, but the effect disappears in several of the largest and best-blinded trials. Because preparations differ so much between studies, pooling them is arguably the wrong thing to do at all.

What may be going on: Alkylamides bind cannabinoid receptors on immune cells and polysaccharides activate macrophages in laboratory work; the human relevance is unclear.

Limited evidence. Early human work, or mostly lab and animal research.

View the 1 source

Deep research mode adds each paper’s own conclusion and stated limitations.

Inflammatory markers

Inflammation
Not enough evidence

There is not enough human research to say echinacea changes inflammatory markers. Most of the immunological work is in cell culture.

Not enough evidence. Not enough human research to say anything useful yet.

View the 4 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Things to know

Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.

  • Allergy

    Asteraceae allergy and anaphylaxis

    Echinacea belongs to the daisy family, alongside ragweed, chrysanthemum and marigold. Rashes, asthma exacerbations and anaphylaxis have been reported, particularly in people with existing atopy, and regulators have advised against use in young children on this basis.

  • Interaction

    Immunosuppressants and CYP substrates

    Interacts withCiclosporin, tacrolimus, CYP3A4 and CYP1A2 substrates

    Its plausible immune-stimulating action makes it a poor combination with ciclosporin, tacrolimus or other immunosuppressants. Human studies also show modest effects on CYP1A2 and CYP3A4 activity, which can shift levels of some medicines.

  • Worth knowing

    Species and part substitution

    Laboratory testing of retail echinacea has repeatedly found the wrong species, the wrong plant part, or no detectable marker compounds. The label frequently does not describe the contents.

  • Worth knowing

    Autoimmune disease

    It is conventionally avoided in autoimmune conditions such as lupus and multiple sclerosis. The reasoning is theoretical rather than based on documented harm, but the theory is the same one used to market it.

  • Worth knowing

    Sold without pre-market review

    In the US no regulator assesses whether an echinacea product works, or whether it contains what the label claims, before it is sold.

Evidence ratings on this page: 1 limited evidence, 1 not enough evidence.

Supplements are sold in the US without pre-market review of efficacy or safety. Nothing on this page is a recommendation to take Echinacea, or a dose to follow.